SUMMARY The regression of small rheumatoid nodules was noted in four patients after starting sulphasalazine therapy. This coincided with an improvement in synovitis and also falls in erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). The relation between the nodule regression and the sulphasalazine therapy is discussed. 
Sulphasalazine (Salazopyrin), an azo compound of sulphapyridine and 5-aminosalicylic acid, was introduced in 1941 for the treatment of rheumatoid arthritis and ulcerative colitis.1 Its effectiveness in the treatment of ulcerative colitis remains undisputed. It quickly fell into disfavour as a treatment for rheumatoid arthritis, however, after a report by Sinclair Although it is possible that nodule regression in four of the five patients occurred spontaneously, the relative infrequency of nodule regression and the temporal relation between introduction of sulphasalazine and the improvement in disease activity strongly suggest that in some way sulphasalazine contributed to both events.
Sulphasalazine has been used for many years in the treatment of ulcerative colitis, but its widespread use as a second line agent in the treatment of rheumatoid arthritis has been relatively recent.3
It is an azo compound of sulphapyridine and 5-aminosalicylic acid (5-ASA): the local action of 5-ASA on the bowel wall is thought to have a predominant role in the drug's activity in ulcerative colitis'2; in rheumatoid arthritis, however, the sulphapyridine moiety is thought to be more important.'3 Just how the drug works as a disease modifying agent remains poorly understood. Both sulphasalazine and sulphapyridine are known to have an inhibitory action on polymorph migration and superoxide production, and 5-ASA and sulphapyridine inhibit polymorph cytotoxicity in vitro.14 Sulphasalazine has also been noted to inhibit mononuclear cell chemotaxis'5 16 
